Skip to main content

Pediatric Rheum

RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
Kawasaki.jpg

What Happened to Kawasaki Disease During COVID-19?

Jun 20, 2022

During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD

Read Article
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.




  1. Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

Jun 04, 2022

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 



Here are my favorite late-breakers from Day 4

Read Article
#EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
Jun 04, 2022
Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
Watch: Juvenile Spondyloarthritis Dr. Pamela Weiss demystifies juvenial SpA and discusses the unique aspects of the disease. https://t.co/xa2mO0fdzq#MedEd https://t.co/6JVUGRx5Go
Dr. John Cush @RheumNow( View Tweet )
May 26, 2022
Israel study of 171 kids w/ MIS-C (med age 8 (5-12): Dx#s - 59 during Alpha , 79 Delta , & 33 Omicron waves. All Rx w/ IVIG + steroids. 6-15% prev recv COVID VAX, none ICU admitted. Worse Dz & higher incidence during alpha wave (54.5/100K) https://t.co/wAby8uKIH4 https://t.co/zc19zeUKpq
Dr. John Cush @RheumNow( View Tweet )
May 20, 2022
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

May 20, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
Dr. Pascual shows that signatures show IFN or plasmablast or PMN/Myeloid signatures, thus identifying 7 subsets of lupus kids #UTSWSLE2022 https://t.co/3BAxPdAKw8
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Insurance delays in starting TNF Inhibitors in kids w/ Juvenile Idiopathic Arthritis (91% on DMARDs) - prior authorization required in 98%; 26% of PA requests denied & required appeals, w/ 22% delays > 2+ wks, 25% took 30+ days to start TNFi https://t.co/1TGmM8qOHR https://t.co/EpbrNSbNBl
Dr. John Cush @RheumNow( View Tweet )
May 05, 2022
Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z
Dr. John Cush @RheumNow( View Tweet )
May 01, 2022
JIA.oligoarticular.jpg

Biologics for JIA? Not So Fast, Say Insurers

MedPage Today
Apr 25, 2022

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.



Among 54 patients seen at Boston Children's Hospital for newly diagnosed JIA in 2018-2019,

Read Article
FDA approved 1st drug for kids with COVID-19. Veklury (remdesivir) get an expanded indication in Peds >28days old & wt > 3 kg who has SARS-CoV-2 & are Hospitalized, or Not hospitalized & at high risk for severe COVID-19 or death https://t.co/7Hn4CwKjxv

Dr. John Cush @RheumNow( View Tweet )

Apr 25, 2022
Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2

Dr. John Cush @RheumNow( View Tweet )

Apr 19, 2022
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today
Apr 14, 2022

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
Your Hot Topic Questions from RNL 2022 Rheumatologists questions for Dr. Jack Cush QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/wpPeIwiCxe https://t.co/UY3gDaVeTv
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
Retrospective cohort hospital study of 228 children with MIS-C; 215 patients (median age 8 yrs, 63% boys) shows that orticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease https://t.co/HLSR5zOseU https://t.co/5z7I9SVcxI
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
Dr. Jonathan Hausman on JIA Most subjects equivalent to adult forms of inflammatory arthritis - note early onset seronegative oligoarthritis Tips on transitioning to adult care - determine extent of active disease vs. chronic damage @RheumNow #RNL2022 https://t.co/MhjH04PQ3e
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
ILAR classifications vs the reality of disease changes seen in pedi clinics is an issue for continuing care. Dr. @hausmannMD reviews arthritis clusters which may make it easier to understand from an adult rheum perspective. #RNL2022 @RheumNow https://t.co/7xYD96R5Rw
Dr. Rachel Tate @uptoTate( View Tweet )
Mar 20, 2022
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article
×